Jonathan A. Pachter

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer”.

Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.01.028

N/A

0.879DataRank · unranked

31 citations

Cem Demirkiran, Tobias M.P. Hartwich, Stefania Bellone, Diego Manavella, Levent Mutlu +10 more

ROCK1 and ROCK2 Are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion

UNC Libraries(2020)10.17615/8wje-qy25

N/A

0DataRank · unranked

0 citations

Hanqing Dong, Sharon L. Campbell, Xin Chen, Linda Castaldo, Channing J. Der +6 more

Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ -Driven Uveal Melanoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3363

N/A

0DataRank · unranked

77 citations

Monica Acosta, Robert Saddawi‐Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes +13 more

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

Blood(2022)10.1182/blood.2021011597

N/A

0DataRank · unranked

134 citations

Shuhua Wang, Kevin Z. Chen, Alexandra Waller, Aditi Sharma, Claudia L. Edgar +14 more

Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy

Gastroenterology(2022)10.1053/j.gastro.2022.06.027

N/A

0DataRank · unranked

76 citations

Jianxin Wang, John Davelaar, Andrew Baker, Keyu Li, Nan Niu +17 more

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

Proceedings of the National Academy of Sciences(2022)10.1073/pnas.2117065119

N/A

0DataRank · unranked

75 citations

Jayanth S. Shankara Narayanan, Jacob R. Andrew, Marjaana Ojalill, A. Barrie, Shulin Jiang +15 more

Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4192

N/A

0DataRank · unranked

6 citations

Zachariah Brown, Sheila Linden, Christina Rodriguez, Omer H. Elmadbouh, Jonathan A. Pachter +9 more

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101244

N/A

0DataRank · unranked

25 citations

Simone Lubrano, Michele Ceribelli, Damiano Cosimo Rigiracciolo, Robert Saddawi‐Konefka, Farhoud Faraji +18 more

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2386

N/A

0DataRank · unranked

7 citations

Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran +11 more

Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4024

N/A

0DataRank · unranked

5 citations

John Davelaar, Jessica Gai, Zachariah Brown, Abrahm Levi, Sheila Linden +15 more

Data from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

(2023)10.1158/1078-0432.c.6529851

N/A

0DataRank · unranked

0 citations

Monica Acosta, Robert Saddawi‐Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes +13 more

Data from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

(2023)10.1158/1078-0432.c.6605170.v2

N/A

0DataRank · unranked

0 citations

Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran +11 more

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0870

N/A

0DataRank · unranked

33 citations

Larry Yan, Fadia Qiryaqos, Lars D. Engstrom, Jade Laguer, Andrew Calinisan +29 more

Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer

Cancer Medicine(2024)10.1002/cam4.70210

N/A

0DataRank · unranked

13 citations

Miranda Mansolf, Cem Demirkiran, Michelle Greenman, Stefania Bellone, Blair McNamara +7 more

Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.04.010

N/A

0DataRank · unranked

9 citations

Michelle Greenman, Stefania Bellone, Blair McNamara, Tobias M.P. Hartwich, Diego Manavella +10 more

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.12.22.629990

N/A

0DataRank · unranked

1 citations

Teagan A. Nathanson, Afshin Varzavand, Adeline A. Hawkins, Rebekah M. Peplinski, Elizabeth Hannan +8 more

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Cancer Cell(2025)10.1016/j.ccell.2025.02.001

N/A

0DataRank · unranked

38 citations

Rodolfo Daniel Cervantes‐Villagrana, Farhoud Faraji, Sydney I. Ramirez, Kuniaki Sato, Sendi Rafael Adame-Garcia +15 more

Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.101943

N/A

0DataRank · unranked

12 citations

Tursun Turapov, David A. Kircher, Karly A. Stanley, Katie M. Culver, A. Paulina Medellin +7 more

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition

Oncogene(2025)10.1038/s41388-025-03603-w

N/A

0DataRank · unranked

2 citations

Teagan A. Nathanson, Afshin Varzavand, Adeline A. Hawkins, Rebekah M. Peplinski, Elizabeth Hannan +8 more

Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.08.02.230839

N/A

0DataRank · unranked

14 citations

Kelsey E. Huntington, Shengliang Zhang, Lindsey Carlsen, Eui‐Young So, Cassandra Parker +16 more

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor

International Journal of Molecular Sciences(2025)10.3390/ijms26188924

N/A

0DataRank · unranked

2 citations

Stefania Bellone, Victoria M. Ettorre, Miranda Mansolf, Tobias M.P. Hartwich, Blair McNamara +11 more